Five-year results of photodynamic therapy with verteporfin for Japanese patients with neovascular age-related macular degeneration

Clinical Ophthalmology

Volumn 7, Issue , 2013, Pages 615-620

  Tsuchihashi, Takashi ^a   Mori, Keisuke ^a   Ueyama, Kazuhiro ^a   Yoneya, Shin ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Age related macular degeneration; Photodynamic therapy; Polypoidal choroidal vasculopathy; Visual outcomes

Indexed keywords

VERTEPORFIN;

AGED; ARTICLE; FEMALE; FOLLOW UP; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PHOTODYNAMIC THERAPY; POLYPOIDAL CHOROIDAL VASCULOPATHY; PROGNOSIS; RETINA MACULA AGE RELATED DEGENERATION; RETREATMENT; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL SYSTEM EXAMINATION;

EID: 84875600362     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S43566     Document Type: Article

References (26)

1. Vingerling LR, Diclemans IJ, Hofman A, et al. The prevalence of age related maculopathy in Rotterdam study. Ophthalmology. 1995;102: 205-210.
2. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Arch Ophthalmol. 1999;117:1329-1345.
3. Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001;131:541-560.
4. Japanese Age-Related Macular Degeneration Trials (JAT) Study Group. Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol. 2003;135:1049-1061.
5. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol. 2001;119:198-207.
6. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial-VIP report no 1. Ophthalmology. 2001;108:841-852.
7. Blinder KJ, Bradley S, Bressler NM, et al. Treatment of Age-related Macular Degeneration with Photodynamic Therapy study group; Verteporfin in Photodynamic Therapy study group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no 1. Am J Ophthalmol. 2003;136:407-418.
8. Barbazetto I, Burdan A, Bressler NM, et al. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group; Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment-TAP and VIP report no 2. Arch Ophthalmol. 2003;121: 1253-1268.
9. Arnold JI, Blinder KJ, Bressler NM, et al. Treatment of Age-related Macular Degeneration with Photodynamic Therapy study group; Verteporfin in Photodynamic Therapy study group. Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no 3. Am J Ophthalmol. 2004;137:683-696.
10. Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol. 1995;39:367-374.
11. Spaide RF, Yannuzzi LA, Slakter JS, Sorenson J, Orlach DA. Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina. 1995;15:100-110.
12. Yannuzzi LA, Ciardella A, Spaide RF, Rabb M, Freund KB, Orlock DA. The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. Arch Ophthalmol. 1997;115:478-485.
13. Yannuzzi LA, Wong DWK, Storzolini BS, et al. Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration. Arch Ophthalmol. 1999;117:1503-1510.
14. Ciardella AP, Donsoff IM, Huang SJ, Costa DL, Yannuzzi LA. Polypoidal choroidal vasculopathy. Surv Ophthalmol. 2004;49:25-37.
15. Sho K, Takahashi K, Yamada H, et al. Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. Arch Ophthalmol. 2003;121:1392-1396.
16. Yuzawa M, Mori R, Kawamura A. The origins of polypoidal choroidal vasculopathy. Br J Ophthalmol. 2005;89:602-607.
17. Maruko I, Iida T, Ssito M, Nagayama D, Saito K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol. 2005;144:15-22.
18. Mori K, Horie-inoue K, Gerhlbach PL, et al. Phenotype and genotype characteristics of age-related macular degeneration in Japanese population. Ophthalmology. 2010;117:928-938.
19. Spaide RF, Donsoff I, Lam DL, et al. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy. Retina. 2002;22: 529-535.
20. Quaranta M, Maget-Faysse M, Coscas G. Exudative idiopathic polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. Am J Ophthalmol. 2002;134:277-280.
21. Chan WM, Lam DS, Lai TY, et al. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy. One-year results of a prospective case series. Ophthalmology. 2004; 111:1576-1584.
22. Lee SC, Seong YS, Kim SS, Koh HJ, Kwon OW. Photodynamic therapy with verteporfin for polypoidal choroidal vasculopathy of the macula. Ophthalmologica. 2004;218:193-201.
23. Silva Rm, Figueira J, Cachulo ML, Duarte L, Faria de Abreu JR, Cunha-Vaz JG. Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol. 2005;243:973-979.
24. Japanese Age-Related Macular Degeneration Trials (JAT) Study Group. Photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD): results of the Japanese AMD Trial (JAT) extension. Jpn J Ophthalmol. 2008;52:99-107.
25. Treatment of Age-Related Macular Degeneration with Photodynamic therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of an open-label extension of 2 randomized clinical trials-TAP report no 8. Graefes Arch Clin Exp Ophthalmol. 2006;244:1132-1142.
26. Honda S, Kurimoto Y, Kagotani Y, Yamamoto H, Takagi H, Uenishi M. Hyogo Macular Disease Study Group. Photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: a 30-month multicenter study in Hyogo, Japan. Jpn J Ophthalmol. 2009;53:593-597.